Three-year results show durable distant metastasis-free survival and RFS benefits with adjuvant pembrolizumab.
Clinical Trials
Fianlimab/Cemiplimab Demonstrates Early Clinical Activity and Safety in Advanced Melanoma
The LAG-3 inhibitor fianlimab plus cemiplimab (Libtayo) produced high and consistent tumor responses and a comparable toxicity profile to that of anti–PD-L1 monotherapies in patients with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study (NCT03005782) presented at the 2023 ASCO Annual Meeting.
Expert: KEYNOTE-716 Could be a “Game-Changer" for Patients with Stage 2 Melanoma At High Risk of Recurrence
Until this study, adjuvant immunotherapy was standard of care for stage 3B melanoma but not stage 2, which has relatively similar survival rates and risk of recurrence.
Nivolumab Plus Relatlimab Demonstrates Consistent Benefit for Patients with Advanced Melanoma
Two-year follow-up data from the RELATIVITY-047 trial (NCT03470922) showed a continued benefit for patients with previously untreated, unresectable, or metastatic melanoma receiving nivolumab plus relatlimab (Opdualag) vs nivolumab (Opdivo) monotherapy supporting the use of the combination, according to Hussein A. Tawbi, MD, PhD.